Dyadic International, Inc.
DYAIAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 23, 2025 | H.C. Wainwright | Swayampakula Ramakanth | $3.00(+173%) | $1.10 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2023 |
| Dawson James | downgrade | Buy →Neutral | Jul 18, 2022 |
| HC Wainwright & Co. | maintain | Buy | Apr 5, 2022 |
| HC Wainwright & Co. | maintain | Buy | Dec 17, 2021 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.03| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.06 | $-0.04 | $961.1K | $1.0M |
| May 13, 2026 | $-0.05 | $-0.04 | $1.1M | $903.8K |
| Mar 25, 2026 | $-0.06 | $-0.03 | $564.3K | $1.3M |
| Nov 12, 2025 | $-0.06 | $-0.04 | $1.2M | $1.3M |
| Aug 13, 2025 | $-0.06 | $-0.06 | $463.4K | $1.5M |
| May 14, 2025 | $-0.07 | — | $393.6K | — |
| Mar 26, 2025 | $-0.05 | $-0.04 | $817.4K | $1.6M |
| Nov 12, 2024 | $-0.01 | $-0.07 | $2.0M | $1.6M |
News
JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results…
Dyadic International (NASDAQ: DYAI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk. Profitability This table compares Dyadic International and
Dyadic International (NASDAQ: DYAI) is moving from technology-platform development toward commercial execution, with multiple products entering the market through its own channels and partnerships, President and Chief Operating Officer Joe Hazelton said at the Lytham Partners Fall 2026 Investor Conference. Hazelton said the company is applying its fungal gene-expression platforms to produce proteins and enzymes for
Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability. Volatility and Risk Amylyx Pharmaceuticals has a beta
Dyadic International Inc. (NASDAQ: DYAI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.72 and traded as low as $0.4351. Dyadic International shares last traded at $0.4660, with a volume of 116,708 shares trading hands. Analyst Upgrades and
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
Dyadic International Inc. (NASDAQ: DYAI - Get Free Report) passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $0.88 and traded as low as $0.3527. Dyadic International shares last traded at $0.4244, with a volume of 490,904 shares. Analysts Set New Price Targets Separately,
JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants…
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing…
Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership. Earnings and Valuation This table compares Dyadic